Home › FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
 

Keywords :   


FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

2015-12-18 22:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced treatment expanded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Sontara Offers Sri Flo Wipes
15.05Eastern North Pacific Tropical Weather Outlook
15.05Atlantic Tropical Weather Outlook
15.05Ally Waste Announces Acquisition of Litterally
15.05Radiowell Launches National Ad Campaign to Remind Consumers to Recycle Radios and Batteries Appropriately
15.05New WM Facility Aims to Reduce Contamination, Improve Recycling in Northwest Florida
15.05Hard to Recycle Items Event in Pittsburgh Sees Hundreds of Residents Participate
15.05Start Your Day with Paul Reidy of Impact Environmental Group
More »